Amdocs cuts 2027 outlook after T-Mobile dispute

The market has responded accordingly. Amdocs shares collapsed to $42.09 on Nov. 6 from $60.25 a month earlier, erasing roughly a third of the company’s value in weeks and leaving the stock deep below both its 50-day moving average and 200-day moving average. The drop came with a surge in volume, a classic sign that institutions are reassessing the name rather than merely taking profits. RSI readings around 19 also show the stock is heavily oversold, but oversold does not mean cheap when the earnings base itself is being rewritten.

The real issue is trust. Telecom software vendors trade on predictability: sticky customers, recurring services, and backlog that helps smooth the cycle. T-Mobile’s shock has punctured that narrative and raised the uncomfortable question investors now have to ask about every large client relationship: if one anchor customer can shift this much business away, how durable is the rest of the book? That is why the selloff is bigger than a single account loss. It is a repricing of execution risk across the entire franchise.

To be clear, the business is not dead. Excluding T-Mobile, Amdocs still points to mid-single-digit growth in its core operations, and it continues to win business in its application and operations software, or aOS, segment. But the market does not pay premium multiples for “ex-T-Mobile” resilience if the company cannot prove that backlog is stabilizing and cash flow is intact. Until management shows that the customer hit is contained, every upside case remains fragile.

Investors should think about this as a two-speed story. On one side, the selloff may tempt value buyers who see a profitable software vendor with a deep telecom footprint. On the other, the downgrade risk is real if other major clients decide to use the T-Mobile episode as leverage in their own negotiations. That is the hidden bear case: not just revenue pressure from one customer, but margin pressure and weaker renewal economics across the portfolio.

The investable question now is whether Amdocs can convert its core business into a cleaner, more diversified growth engine, or whether the T-Mobile shock becomes the start of a longer de-rating. For now, the market is voting with its feet. I would treat Amdocs as a wait-and-see turnaround, not a bargain, until backlog, revenue and free cash flow stop deteriorating.